Bioline Rx Ltd Ord

(BLNEF)

By |

Profile

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.

Contact Information

Website: www.biolinerx.com
Email: IR@biolinerx.com
Main Phone: +972 86429100
Address: 2 HaMa'ayan Street
City / Town: Modi'in
Country: IL
Postal Code: 7177871

Issuer Information

Exchange: GREY
CEO: Philip Serlin
Employees: 42

Equities News

Profile

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.

Contact Information

Website: www.biolinerx.com
Email: IR@biolinerx.com
Main Phone: +972 86429100
Address: 2 HaMa'ayan Street
City / Town: Modi'in
Country: IL
Postal Code: 7177871

Issuer Information

Exchange: GREY
CEO: Philip Serlin
Employees: 42

Equities News

$ 0.86 $ 0. (0.00%)
Last Price 0.86 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close 0.86
Last Trade Volume 0 52 Wk Hi N/A 52 Wk Low N/A
Market Cap 91.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 318,381,460.00 EPS (TTM) -0.27 PE Ratio N/A Exchange Greys